Emerging issues in ulcerative colitis and ulcerative proctitis: Individualizing treatment to maximize outcomes

Gastroenterology and Hepatology

Volumn 5, Issue 6 SUPPL. 15, 2009, Pages 1-16

  Hanauer, Stephen B ^a   Present, Daniel H ^b   Rubin, David T ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BECLOMETASONE; BUDESONIDE; CALGRANULIN; CORTISONE; ENEMA; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; SALAZOSULFAPYRIDINE; TINIDAZOLE;

CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON CANCER; CONFERENCE PAPER; CYTOMEGALOVIRUS; DISEASE SEVERITY; DRUG COST; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG POTENTIATION; HEALING; HUMAN; ILEITIS; INTESTINE MOTILITY; INTESTINE MUCOSA; MAINTENANCE THERAPY; MEDICAL DECISION MAKING; MEDICAL PRACTICE; PATIENT COMPLIANCE; PROCTITIS; PROCTOSIGMOIDITIS; PROSTATE CANCER; RADIATION INJURY; RECTUM CANCER; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS; UTERINE CERVIX CANCER;

EID: 69749083197     PISSN: 15547914     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (21)

1. Loftus EV, Silverstein MD, Sandborn WJ, et al. Ulcerative colitis in Olmstead county, Minnesota, 1940-1993: Incidence, prevalence and survival. Gut 2000;46:336-343.
2. Kornbluth A, Sachar B. Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371-1385. (Pubitemid 39062279)
3. Farmer RG, Easley KA, Rankin GB. Dig Dis Sci. 1993;38:1137-1146.
4. Safdi M, DeMicco M, Sninsky C, et al. A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol. 1997;92:1867-1871. (Pubitemid 27440908)
5. Lichtenstein GR, Kamm MA, Sandborn WJ, et al. MMX mesalazine for the induction of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations. Aliment Pharmacol Ther. 2008;1:1094-1102.
6. Mulder CJ, Fockens P, Meijer JW, et al. Beclomethasone dipropionate (3Mg) versus 5-aminosalycylic acid (2g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8:549-553. (Pubitemid 26229963)
7. Marteau P, Probert CS, Lindgren S, et al. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis. Gut. 2005;54:960-965.
8. Carter MJ, Lobo AJ, Travis SPL. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53(Suppl V):v1-v16.
9. Travis SPL, Stange EF, Lémann M, et al. European evidence-based consensus on the management of ulcerative colitis: current management. Gut 2006;55(Suppl I):i16-i35. (Pubitemid 43268291)
10. Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ. 1992;305:20-22.
11. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476. (Pubitemid 41770166)
12. Farmer RG. Long-term prognosis for patients with ulcerative proctosigmoiditis (ulcerative colitis confined to the rectum and sigmoid colon). J Clin Gastroenterol. 1979;1:47-50.
13. Farmer RG. Clinical patterns, natural history, and progression of ulcerative colitis. A long-term follow-up of 1116 patients. Dig Dis Sci. 1993;38:1137-1146.
14. Huo D, Rothe JA, Rubin DT, et al. Increased inflammatory activity is an independent risk factor for dysplasia and colorectal cancer in ulcerative colitis: a case-control analysis with blinded prospective pathology review. Oral presentation at Digestive Disease Week, May 20-25, 2006, Los Angeles, CA. Abstract 14.
15. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in long-standing ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:11813-11816
16. Frøslie KF, Jahnsen J, Mourn BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007;133:412-422. (Pubitemid 47187355)
17. Shen B, Remzi FH, Lavery IC, et al. A proposed classification of ileal pouch disorders and associated complications after restorative proctocolectomy. Clin Gastroenterol Hepatol. 2008;6:145-158. (Pubitemid 351172940)
18. Shen B, Lashner B. Diagnosis and treatment of ileal pouch diseases in patients with underlying ulcerative colitis. Curr Treat Options Gastroenterol 2006;9:3-12.
19. Shen B, Lashner BA, Bennett AE, et al. Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. Am J Gastroenterol 2004;99:1527-1531. (Pubitemid 39180102)
20. Maser EA, Present DH. Pouch-ouch. Curr Opin Gastroenterol. 2008;24:70-74.
21. Jahraus CD, Bettenhausen D, Malik U, et al. Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients. In J Radiat Oncol Biol Phys. 2005;63:1483-1487. (Pubitemid 41628046)